BeOne Medicines AG/$ONC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BeOne Medicines AG
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
- Ticker
- $ONC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 12,000
- Headquarters
- Basel, Switzerland
- Website
- beonemedicines.com
ONC Metrics
BasicAdvanced
$46B
51.17
$7.81
0.63
-
Price and volume
Market cap
$46B
Beta
0.63
52-week high
$424.73
52-week low
$253.95
Average daily volume
415K
Financial strength
Current ratio
3.55
Quick ratio
3.102
Long term debt to equity
0.289
Total debt to equity
0.354
Interest coverage (TTM)
8.31%
Profitability
EBITDA (TTM)
1,328.759
Gross margin (TTM)
89.39%
Net profit margin (TTM)
13.86%
Operating margin (TTM)
17.84%
Effective tax rate (TTM)
19.07%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
8.41%
Return on equity (TTM)
18.40%
Valuation
Price to earnings (TTM)
51.17
Price to revenue (TTM)
6.761
Price to book
7.84
Price to tangible book (TTM)
7.89
Price to free cash flow (TTM)
31.264
Free cash flow yield (TTM)
3.20%
Free cash flow per share (TTM)
12.785
Growth
Revenue change (TTM)
32.86%
Earnings per share change (TTM)
1,206.30%
3-year revenue growth (CAGR)
41.48%
10-year revenue growth (CAGR)
102.33%
3-year earnings per share growth (CAGR)
-8.63%
10-year earnings per share growth (CAGR)
5.78%
What the Analysts think about ONC
Analyst ratings (Buy, Hold, Sell) for BeOne Medicines AG stock.
Analyst projections of the future price of BeOne Medicines AG stock.
Bulls say / Bears say
BRUKINSA remains a strong growth engine: global sales rose 34% in the third quarter, with U.S. sales topping $1 billion, and the FDA gave priority review to an application that could add first-line mantle cell lymphoma use. (SEC)
Profitability is scaling alongside sales. Third-quarter GAAP operating income rose 157% and free cash flow increased 34%, prompting BeOne to raise its 2026 revenue and operating-income guidance. (SEC)
BeOne is building growth beyond BRUKINSA: TEVIMBRA sales increased 28% in the quarter, and the FDA approved a TEVIMBRA-based regimen for first-line HER2-positive gastroesophageal cancer. Several solid-tumour programmes are also advancing towards pivotal trials. (BeOne Medicines, Business Wire)
The business remains concentrated in BRUKINSA, which accounted for roughly three-quarters of third-quarter revenue. U.S. sales also benefited from about $50 million of order timing and an extra shipping day, making that quarter’s growth somewhat flattered. (The Motley Fool)
Management expects higher Medicare Part D manufacturer liability to turn a modest 2026 pricing benefit into a flat-to-modest headwind in 2027, which could weigh on BRUKINSA economics. (The Motley Fool)
The Amgen-licensed portfolio faces potential sales pressure beyond 2026: BeOne flagged biosimilar competition for XGEVA and possible value-based purchasing inclusion for XGEVA and KYPROLIS. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
ONC Financial Performance
Revenues and expenses
ONC Earnings Performance
Company profitability
Upcoming events
No upcoming events
ONC News
AllArticlesVideos

CLL Society and BeOne Medicines Announce Expanded Partnership to Advance Education and Support Across the CLL/SLL Community
Business Wire3 days ago

BeOne Medicines Q3 Earnings Call Highlights
MarketBeat2 weeks ago

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
Business Wire2 weeks ago
Funds containing ONC
AllUSDEUR
Fund name | Fund size | $ONC weighting |
|---|---|---|
iShares China Large Cap£FXC | $737M | 2.35% |
iShares Dow Jones China Offshore 50€EXXU | €42M | 2.23% |
iShares MSCI China€ICGA | $2.4B | 1.11% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.97% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.97% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.